News & Updates

Show Multimedia Only

Inactive disease a viable target in tofacitinib-treated patients with JIA

16 Sep 2025 by

Treatment with tofacitinib improves the rates of Juvenile Arthritis Disease Activity Score (JADAS) in 10 joints (JADAS10)-clinically inactive disease (CID) and American College of Rheumatology (ACR)-CID in patients with juvenile idiopathic arthritis (JIA), with improvements sustained over time, a study has shown. Additionally, a few patients have achieved JADAS10 remission.

Inactive disease a viable target in tofacitinib-treated patients with JIA

16 Sep 2025

Hydroxychloroquine falls flat for RA prevention in at-risk individuals

15 Sep 2025

Treatment with hydroxychloroquine (HCQ) for 12 months does not appear to prevent the development of rheumatoid arthritis (RA) among at-risk individuals, as shown in a phase II study.

Hydroxychloroquine falls flat for RA prevention in at-risk individuals

15 Sep 2025

ALONE-AF: Safe to stop anticoagulant therapy after AF ablation for recurrence-free patients

15 Sep 2025 by

For individuals without documented recurrence for at least a year following catheter ablation for atrial fibrillation (AF), discontinuing oral anticoagulant therapy results in more favourable outcomes than when continued, according to the ALONE-AF trial.

ALONE-AF: Safe to stop anticoagulant therapy after AF ablation for recurrence-free patients

15 Sep 2025

What’s hot at APS & MCV 2025?

15 Sep 2025

MIMS Doctor brings you extensive coverage of the Asia Pneumonia Summit & MasterClass in Vaccinology 2025, held recently in Taipei, Taiwan. Check out the latest updates on RSV, pneumococcal disease, new vaccines, plus thought-provoking insights from respiratory experts. [READ THE FULL REPORT]

What’s hot at APS & MCV 2025?

15 Sep 2025

GLP-1RAs look good for idiopathic intracranial hypertension

14 Sep 2025 by

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) appear promising in the management of idiopathic intracranial hypertension, with a retrospective study showing that the drugs reduce symptom burden as well as the need for medications and invasive procedures.

GLP-1RAs look good for idiopathic intracranial hypertension

14 Sep 2025

Mepolizumab cuts exposure to OCS in severe eosinophilic asthma

14 Sep 2025

In patients with severe eosinophilic asthma, treatment with mepolizumab reduces exposure to toxic levels of oral corticosteroids (OCS) and, in turn, the incidence of associated complications, according to a real-world study.

Mepolizumab cuts exposure to OCS in severe eosinophilic asthma

14 Sep 2025

Postpartum bleeding lower with prophylactic carbetocin vs oxytocin

13 Sep 2025 by

First-line prophylactic treatment with carbetocin during the third stage of labour works better than oxytocin at reducing the risk of postpartum haemorrhage (PPH), according to a study from Australia.

Postpartum bleeding lower with prophylactic carbetocin vs oxytocin

13 Sep 2025

Enzalutamide plus radium-223 improves rPFS in mCRPC

12 Sep 2025 by

First-line treatment with enzalutamide plus radium-223 (Ra223) results in significant improvements in radiological progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the EORTC 1222/PEACE-3 trial have shown.

Enzalutamide plus radium-223 improves rPFS in mCRPC

12 Sep 2025

TALENTACE supports atezolizumab + bevacizumab after TACE for HCC

12 Sep 2025 by

Findings from the TALENTACE trial presented at ESMO GI 2025 support the combination of atezolizumab and bevacizumab after transarterial chemoembolization (TACE) for the treatment of individuals with systemically untreated, intermediate-to-high tumour burden, unresectable hepatocellular carcinoma (HCC).

TALENTACE supports atezolizumab + bevacizumab after TACE for HCC

12 Sep 2025

Vericiguat misses endpoint in HFrEF trial

12 Sep 2025

In the treatment of patients with heart failure and reduced ejection fraction (HFrEF) and no recent worsening, the use of vericiguat falls short of reducing the risk of the composite of cardiovascular death and HF hospitalization, as shown in a phase III study.

Vericiguat misses endpoint in HFrEF trial

12 Sep 2025

News & Updates

Filter by Specialty:

Specialty:

Inactive disease a viable target in tofacitinib-treated patients with JIA

Inactive disease a viable target in tofacitinib-treated patients with JIA

Hydroxychloroquine falls flat for RA prevention in at-risk individuals

Hydroxychloroquine falls flat for RA prevention in at-risk individuals

ALONE-AF: Safe to stop anticoagulant therapy after AF ablation for recurrence-free patients

ALONE-AF: Safe to stop anticoagulant therapy after AF ablation for recurrence-free patients

What’s hot at APS & MCV 2025?

What’s hot at APS & MCV 2025?

GLP-1RAs look good for idiopathic intracranial hypertension

GLP-1RAs look good for idiopathic intracranial hypertension

Mepolizumab cuts exposure to OCS in severe eosinophilic asthma

Mepolizumab cuts exposure to OCS in severe eosinophilic asthma

Postpartum bleeding lower with prophylactic carbetocin vs oxytocin

Postpartum bleeding lower with prophylactic carbetocin vs oxytocin

Enzalutamide plus radium-223 improves rPFS in mCRPC

Enzalutamide plus radium-223 improves rPFS in mCRPC

TALENTACE supports atezolizumab + bevacizumab after TACE for HCC

TALENTACE supports atezolizumab + bevacizumab after TACE for HCC

Vericiguat misses endpoint in HFrEF trial

Vericiguat misses endpoint in HFrEF trial